WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
+12.81%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.5B
Cap. Flow
% of AUM
13.19%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| 1 |
Microsoft
MSFT
|
$247M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$152M |
| 3 |
Brown & Brown
BRO
|
$120M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
$113M |
| 5 |
Akero Therapeutics
AKRO
|
$106M |
Top Sells
| 1 |
Lam Research
LRCX
|
$144M |
| 2 |
MetLife
MET
|
$97.2M |
| 3 |
Travelers Companies
TRV
|
$91.9M |
| 4 |
Electronic Arts
EA
|
$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
$80.3M |
Sector Composition
| 1 | Healthcare | 25.08% |
| 2 | Technology | 24.07% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAEP
801
Cantor Equity Partners III, Inc. Class A Ordinary Shares
CAEP
$361M
| $1.06M | 0.01% |
+100,000
| New | +$1.06M |
|
802
Hasbro
HAS
$11.2B
| $1.05M | 0.01% |
14,230
+3,152
| +28% | +$233K |
|
803
Ingersoll Rand
IR
$32.2B
| $1.03M | 0.01% |
12,383
+4,354
| +54% | +$362K |
|
804
Oculis Holding
OCS
$901M
| $982K | 0.01% |
+50,568
| New | +$982K |
|
805
Norwegian Cruise Line
NCLH
$11.6B
| $979K | 0.01% |
48,270
+11,121
| +30% | +$226K |
|
806
Iovance Biotherapeutics
IOVA
$901M
| $976K | 0.01% |
567,680
+765
| +0.1% | +$1.32K |
|
807
Fractyl Health
GUTS
$65.4M
| $969K | 0.01% |
597,841
+80,920
| +16% | +$131K |
|
808
Tyra Biosciences
TYRA
$674M
| $958K | 0.01% |
100,108
| – | – |
|
809
Generac Holdings
GNRC
$10.6B
| $914K | ﹤0.01% |
6,383
+1,347
| +27% | +$193K |
|
810
MarketAxess Holdings
MKTX
$7.01B
| $905K | ﹤0.01% |
4,052
+867
| +27% | +$194K |
|
811
Molson Coors Class B
TAP
$9.96B
| $891K | ﹤0.01% |
18,534
+3,988
| +27% | +$192K |
|
812
Wynn Resorts
WYNN
$12.6B
| $891K | ﹤0.01% |
9,508
+1,940
| +26% | +$182K |
|
813
Surgery Partners
SGRY
$2.89B
| $882K | ﹤0.01% |
39,688
-485,712
| -92% | -$10.8M |
|
814
Cirrus Logic
CRUS
$5.94B
| $874K | ﹤0.01% |
8,383
+4,566
| +120% | +$476K |
|
815
Bio-Techne
TECH
$8.46B
| $871K | ﹤0.01% |
16,936
+3,580
| +27% | +$184K |
|
816
Lyell Immunopharma
LYEL
$233M
| $870K | ﹤0.01% |
+98,425
| New | +$870K |
|
|
CHYM
817
Chime Financial, Inc. Class A Common Stock
CHYM
$9.05B
| $863K | ﹤0.01% |
+25,000
| New | +$863K |
|
818
ScottsMiracle-Gro
SMG
$3.64B
| $859K | ﹤0.01% |
13,030
-157,598
| -92% | -$10.4M |
|
819
Kura Oncology
KURA
$713M
| $841K | ﹤0.01% |
145,704
| – | – |
|
|
PARA
820
DELISTED
Paramount Global Class B
PARA
| $839K | ﹤0.01% |
65,013
-1,330,929
| -95% | -$17.2M |
|
821
Nkarta
NKTX
$161M
| $830K | ﹤0.01% |
500,166
| – | – |
|
822
AES
AES
$9.21B
| $809K | ﹤0.01% |
76,911
+16,839
| +28% | +$177K |
|
823
Franklin Resources
BEN
$13B
| $799K | ﹤0.01% |
33,497
+7,308
| +28% | +$174K |
|
824
Fate Therapeutics
FATE
$116M
| $798K | ﹤0.01% |
712,650
-711,517
| -50% | -$797K |
|
825
Albemarle
ALB
$9.6B
| $797K | ﹤0.01% |
+12,711
| New | +$797K |
|